scholarly journals The Factors Effective on Bone Mineral Density in Peritoneal Dialysis Patients

2013 ◽  
Vol 10 (4) ◽  
Author(s):  
Oktay Özkan ◽  
Savaş Öztürk ◽  
Serhat Karadağ ◽  
Meltem Gürsu ◽  
Abdullah Şumnu ◽  
...  
2012 ◽  
Vol 46 (6) ◽  
pp. 454-460 ◽  
Author(s):  
Seok Hui Kang ◽  
Kyu Hyang Cho ◽  
Jong Won Park ◽  
Kyung Woo Yoon ◽  
Jun Young Do

2005 ◽  
Vol 24 (1) ◽  
pp. 79-86 ◽  
Author(s):  
Fettah Fevzi Ersoy ◽  
Stauros Ploumis Passadakis ◽  
Paul Tam ◽  
Evaggelos Dimitros Memmos ◽  
Pericles Konstantinos Katopodis ◽  
...  

2016 ◽  
Vol 21 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Yu-Li Lin ◽  
Yu-Hsien Lai ◽  
Chih-Hsien Wang ◽  
Chiu-Huang Kuo ◽  
Hung-Hsiang Liou ◽  
...  

1998 ◽  
Vol 89 (7) ◽  
pp. 629-634 ◽  
Author(s):  
Noriaki Tokuda ◽  
Jiro Uozumi ◽  
Joichi Kumazawa ◽  
Takenari Yamasaki ◽  
Motonori Kano

Medicina ◽  
2020 ◽  
Vol 56 (9) ◽  
pp. 464
Author(s):  
Armando Raimundo ◽  
Zelinda Charrua ◽  
Nuno Batalha ◽  
Catarina Pereira ◽  
Jose Parraca ◽  
...  

Background and objectives: Peritoneal dialysis (PD) patients are expected to present lower levels of physical activity, unhealthy changes at the body composition level, and low levels of strength. Firstly, this study aimed to report the sex differences in physical activity, body composition and muscle strength and the relations among these variables. Secondly, we analyze the relationship between physical activity and biochemical parameters. Materials and Methods: Thirty-four patients (13 women and 21 men) participated in this study. Body composition was assessed by bioimpedance and dual-energy X-ray absorptiometry (DXA), and maximum isokinetic unilateral strength, analytical parameters and physical activity levels were evaluated. Results: The men showed higher values for weight, height, lean body mass, bone mineral content, bone mineral density (BMD) and total body water, while women showed higher values for the percentage of fat mass and hydration of lean body mass (p < 0.05). No differences between the sexes were found in different levels of physical activity; however, males registered significantly higher values for isokinetic strength variables except for knee extensor strength. BMD was positively related to sedentary activity and negatively related to moderate and vigorous activity (r = 0.383 and r = −0.404, respectively). Light physical activity was negatively correlated with albumin (r = −0.393) and total protein (r = −0.410) levels, while moderate/vigorous activity was positively correlated with urea distribution volume (r = 0.446) and creatinine clearance (r = 0.359) and negatively correlated with the triglyceride level (r = −0.455). Conclusions: PD patients with higher levels of physical activity present better results in terms of body composition and biochemical parameters. Additional studies should be conducted to clarify the relation between physical activity level and BMD.


2002 ◽  
Vol 30 (6) ◽  
pp. 566-575 ◽  
Author(s):  
T Sugimoto ◽  
M Yamakado ◽  
K Matsushita ◽  
T Iwamoto ◽  
H Tagawa

Prevention of osteoporosis and renal osteodystrophy are important for the long-term quality of life in dialysis patients. We examined whether administration of menatetrenone (vitamin K2) improves bone metabolism in continuous ambulatory peritoneal dialysis (CAPD) patients. Administration of a single dose of menatetrenone (15 mg) revealed that the 24-h pharmacodynamics in CAPD patients were comparable to those in control individuals. In a 12-month period of oral menatetrenone administration (45 mg/day), eight stable CAPD patients were studied for blood-bone metabolism parameters and for bone mineral content. Blood concentration of menatetrenone was detectable during the experiment period. Only at 12 months did active vitamin D3 and bone-type alkaline phosphatase (ALP) fall significantly, while total ALP rose significantly. Bone mineral density measured by dual-energy X-ray absorptiometry remained at the same level throughout the study period, suggesting that menatetrenone may protect against bone mineral loss in CAPD patients. These results show that the same dose of oral menatetrenone can be given to CAPD patients as to control individuals, and that menatetrenone can be used safely for 1 year in CAPD patients.


Sign in / Sign up

Export Citation Format

Share Document